In addition to the NIH NSCLC drug list, updated as of October 23rd, 20231, the first c-ROS oncogene 1 (ROS1) TKI for NSCLC named repotrectinib was approved on November 15th, 20232 (Table 1). Here, ROS1 is linked to non-small cell lung carcinoma.